Mostrando 21 - 40 Resultados de 45 Para Buscar '"Sharp and Dohme"', tiempo de consulta: 0.30s Limitar resultados
  1. 21
    “…Falsey, MD, BioFire Diagnostics: Grant/Research Support|Janssen: Grant/Research Support|Merck, Sharp and Dohme: Grant/Research Support|Novavax: Advisor/Consultant|Pfizer: Grant/Research Support Angela R. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    330. BioFire ® FilmArray® Pneumonia Panel (PN) Results Compared to Standard Microbiologic Testing and Clinical Adjudication in Adults Hospitalized with Respiratory Illness.
  2. 22
    “…STUDY FUNDING/COMPETING INTERESTS: This study was supported by Merck Sharp and Dohme. The authors state that they have no financial or commercial conflicts of interest. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Corifollitropin alfa vs recombinant FSH for controlled ovarian stimulation in women aged 35–42 years with a body weight ≥50 kg: a randomized controlled trial
  3. 23
    “…(Employee) Kara Bickham, MD, Merck Sharp and Dohme (Employee, Shareholder)…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1184. A Phase 3, Multicenter, Randomized, Double-blind Study to Evaluate the Interchangeability of V114 and Prevnar 13™ with Respect to Safety, Tolerability, and Immunogenicity in Healthy Infants (PNEU-DIRECTION)
  4. 24
    “…Richard Hobbs, FMedSci, AstraZeneca: Grant/Research Support|National Institute for Health and Care Research: Grant/Research Support|UK Research and Innovation: Grant/Research Support Hugh Montgomery, MD, AstraZeneca: Advisor/Consultant|Millfield Medical Electronics Ltd: Advisor/Consultant Francisco Padilla, MD, Amgen: Grant/Research Support|AstraZeneca: Grant/Research Support|Boehringer Ingelheim: Grant/Research Support|Ferrer: Grant/Research Support|Kowa: Grant/Research Support|Medix: Grant/Research Support|Merck: Grant/Research Support|Merck Sharp and Dohme: Grant/Research Support|Novartis: Grant/Research Support|Pfizer: Grant/Research Support|Sanofi: Grant/Research Support|Servier: Grant/Research Support|Silanes: Grant/Research Support Jesus Abraham Simón Campos, MD, AstraZeneca: Expert Testimony|Atea: Advisor/Consultant|Eli Lilly: Advisor/Consultant|Pfizer: Expert Testimony|Regeneron: Expert Testimony|Roche: Expert Testimony Douglas Arbetter, MPH, AstraZeneca: Employement|AstraZeneca: Stocks/Bonds Seth Seegobin, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Alexandre Kiazand, MD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Katie Streicher, PhD, AstraZeneca: Employee|AstraZeneca: Stocks/Bonds Nuria Martinez-Alier, PhD, AstraZeneca: Employee|AstraZeneca: Employement|AstraZeneca: Stocks/Bonds|AstraZeneca: Stocks/Bonds Taylor Cohen, PhD, AstraZeneca: Employement|AstraZeneca: Stocks/Bonds Mark T. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    529. Safety of AZD7442 (Tixagevimab/Cilgavimab) for Treatment of Mild-to-Moderate COVID-19: 15-Month Final Analysis of the TACKLE Phase 3 Study
  5. 25
    “…N.L.V. reports consultancy and conference fees from Ferring, Merck and Merck Sharp and Dohme. The remaining authors declare no competing interests in relation to the work presented. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Standardizing definitions and reporting guidelines for the infertility core outcome set: an international consensus development study  
  6. 26
    “…N.L.V. reports consultancy and conference fees from Ferring, Merck and Merck Sharp and Dohme. The remaining authors declare no competing interests in relation to the work presented. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Developing a core outcome set for future infertility research: an international consensus development study  
  7. 27
    “…Dabora:Takeda: Current Employment. Jackson:Merck Sharp and Dohme: Honoraria; Chugai: Honoraria; Amgen: Honoraria; Janssen: Honoraria; Celgene: Honoraria; Takeda: Honoraria; Roche: Honoraria.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Delivering Systemic Anti-Cancer Treatment Via Another Route of Administration As an Option to Reduce Exposure to COVID-19 in Patients with Multiple Myeloma in the UK
  8. 28
    “…(Employee, Shareholder) Gretchen Tamms, B.S., Merck Sharp and Dohme (Employee, Shareholder) Luwy Musey, MD, Merck & Co., Inc. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1050. Phase 3 Trial to Evaluate the Safety, Tolerability, and Immunogenicity of V114 Followed by 23valent Pneumococcal Polysaccharide Vaccine 6 Months Later in At-risk Adults Aged 18–49 Years (PNEU-DAY): A Subgroup Analysis by Baseline Risk Factors
  9. 29
    “…L.N.V. receives speaker fees and conferences from Merck, Merck Sharp and Dohme (MSD) and Ferring and research grants from MSD and Ferring. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Cumulative delivery rate per aspiration IVF/ICSI cycle in POSEIDON patients: a real-world evidence study of 9073 patients
  10. 30
    “…N.L.V. reports consultancy and conference fees from Ferring, Merck and Merck Sharp and Dohme. The remaining authors declare no competing interests in relation to the present work. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Top 10 priorities for future infertility research: an international consensus development study  
  11. 31
    “…Hoffmann-La Roche: Consultancy, Honoraria, Research Funding; Foundation Medicine: Consultancy, Honoraria; Illumina: Consultancy, Honoraria, Research Funding; Janssen: Consultancy, Honoraria; Merck Sharp and Dohme: Consultancy, Honoraria, Research Funding; Merck Serono: Consultancy, Honoraria, Research Funding; Merrimack: Consultancy, Honoraria; Novartis: Consultancy, Honoraria, Research Funding; Pharma Mar: Consultancy, Honoraria; Pfizer: Consultancy, Honoraria, Research Funding; Regeneron: Consultancy, Honoraria; Sanofi: Consultancy, Honoraria; Seattle Genetics: Consultancy, Honoraria; Takeda: Consultancy, Honoraria; Vaccibody: Consultancy, Honoraria; Biodesix: Research Funding; Daiichi Sankyo: Consultancy, Honoraria; Clovis: Consultancy, Honoraria, Research Funding; Bayer: Consultancy, Honoraria; AstraZeneca: Consultancy, Honoraria, Research Funding; Abbvie: Consultancy, Honoraria; Amgen: Consultancy, Honoraria, Research Funding. …”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Incidence of and Risk Factors for Venous Thromboembolism Among Hospitalized Patients with Cancer and COVID-19: Report from the COVID-19 and Cancer Consortium (CCC19) Registry
  12. 32
    “…Aitken, PharmD, Melinta Therapeutoics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1831. Machine Learning Approaches to Predicting Resistance in Pseudomonas aeruginosa
  13. 33
    “…Aitken, PharmD, Melinta Therapeutoics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2674. Microbiome and Cumulative Antibiotic Use as Predictors of Stenotrophomonas maltophilia Infection in Patients with Acute Myeloid Leukemia Receiving Remission-Induction Chemotherapy
  14. 34
    “…Aitken, PharmD, Melinta Therapeutics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    605. Identification of a Novel CMY-Variant Enzyme in a Clinical Escherichia coli Strain with Treatment-Emergent Ceftazidime–Avibactam Resistance
  15. 35
    “…The sample size is determined by a predefined quantity of ceftolozane-tazobactam to be supplied by Merck, Sharpe and Dohme (MSD). We anticipate that a trial with 600 patients contributing to the primary outcome analysis would have 80% power to declare non-inferiority with a 5% non-inferiority margin, assuming a 30-day mortality of 5% in both randomised groups. …”
    Enlace del recurso
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    Ceftolozane-tazobactam versus meropenem for definitive treatment of bloodstream infection due to extended-spectrum beta-lactamase (ESBL) and AmpC-producing Enterobacterales (“MERINO-3”): study protocol for a multicentre, open-label randomised non-inferiority trial
  16. 36
    “…Aitken, PharmD, Melinta Therapeutics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    1719. Incidence and Characterization of Invasive Fungal Infections (IFIs) in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib (IBR)
  17. 37
    “…Aitken, PharmD, Melinta Therapeutoics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2682. Prophylaxis-Driven Molecular Epidemiology of Pseudomonas aeruginosa Bloodstream Infections in Adults With Leukemia
  18. 38
    “…Aitken, PharmD, Melinta Therapeutoics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2248. Clinical and Microbiological Outcomes Associated with Real-World Use of Ceftolozane/Tazobactam
  19. 39
    “…Aitken, PharmD, Melinta Therapeutics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    622. The Accessory Genome in Enterococcal Bacteremia: Results from the Vancomycin-Resistant Enterococcal Bacteremia Outcomes Study (VENOUS)
  20. 40
    “…Aitken, PharmD, Melinta Therapeutoics: Grant/Research Support, Research Grant; Merck, Sharpe, and Dohme: Advisory Board; Shionogi: Advisory Board.…”
    Enlace del recurso
    Enlace del recurso
    Online Artículo Texto
    2246. Improved Outcomes for Cancer Patients Treated With Ceftazidime–Avibactam vs. Polymyxin-Containing Regimens for Carbapenem-Resistant Enterobacteriaceae Bacteremia
Herramientas de búsqueda: RSS